Lemzoparlimab Data Readout at ESMO 2022

Presentation details

Abstract Title:   Lemzoparlimab, a Differentiated Anti-CD47 Monoclonal Antibody, in Combination with Azacitidine (AZA) in Patients with Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS): Initial Clinical Results

Abstract #:   3823

First author: Prof. Zhijian Xiao, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences

Session:  Proffered Paper

Date and Time:   Tuesday, September 13, 2022